PTJA12 – Glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy – Final assessment now available
This is the pharmaceutical Joint Assessment PTJA12 – on glasdegib for the treatment of acute myeloid leukaemia (AML). In June 2020, the European Commission granted marketing authorisation for Daurismo® (glasdegib), in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary AML in adult patients who are not candidates for standard […]
EUnetHTA Covid-19 Response
To help in the development of a coordinated response to the Covid-19 pandemic, it is essential that researched, timely and reliable information can be made available to all stakeholders, whether healthcare professionals or members of the public. With this in mind, EUnetHTA has taken the decision to prioritise Covid-19-related initiatives above other work for the […]
EUnetHTA Open Call for Early Dialogue Requests
The EUnetHTA ED Secretariat is holding an Open Call to fill the slots available for EDs through May 31, 2021. EUnetHTA will aim to conduct 1 ED per month with a maximum 8 EDs during the EUnetHTA prolongation period. The Open Call will remain open from July 3, 2020 through to August 15, 2020. Once […]
EUnetHTA Early Dialogues – Status during EUnetHTA prolongation period
The current pandemic situation has put additional strain on European health systems and HTA bodies have not been immune to this impact. The unfortunate result of this has been the temporary suspension of EUnetHTA Early Dialogues (EDs). We are pleased to announce that the EUnetHTA Executive Board has recognized the interest to continue to offer […]
RCR OT 01 – “Rapid collaborative review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic” – final assessment now available
EUnetHTA is pleased to announce that the “Rapid Collaborative Review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic” is now available. This is the first rapid review assessing health technologies for SARS-CoV-2. The general objective of this assessment was to provide a reliable synthesis of the […]
OTCA21 ‘Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea’ Final Assessment now available
EUnetHTA is pleased to announce that the OTCA21 Final Assessment is now available for access. The assessed technology is Hypoglossal Nerve Stimulation (HGNS) for treatment of obstructive sleep apnea. The aim of this assessment was to evaluate effectiveness and safety of HGNS compared with no treatment in those adult patients with moderate-to-severe obstructive sleep apnea […]
PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options – Final assessment now available
This is the pharmaceutical Joint Assessment PTJA11 – Cefiderocol for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. In April 2020, the European Commission granted marketing authorisation for Fetcroja® (cefiderocol) for the treatment of infections due to aerobic Gram-negative bacteria in adult patients with limited treatment options. […]
EUnetHTA 2019 Forum Paper now available for access
We are happy to announce that our paper, ‘The fourth edition of the European Network for Health Technology Assessment: highlights and outcomes’, has been published this week on the International Journal of Technology Assessment in Health Care. The paper is available at this link: Thank you for your cooperation and congratulations to all those involved. Giovanni […]
Statement on the Joint Action 3 Prolongation
EUnetHTA Joint Action 3 has received official approval from Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) for an extension of an additional 12 months without additional funding. This prolongation is meant to allow the finalisation of outstanding deliverables and, where possible, further prepare for a future European HTA system. The Executive Board is currently […]
EUnetHTA 2020 Assembly – Welcome Guide now available
The annual EUnetHTA Assembly aims to provide an overview into the year’s activity, while stimulating discussion on HTA-related topics and looking to the network’s next steps and future developments. Due to current events, we will be holding the 1st April Assembly online with network members, while this year’s Forum is postponed till a later date. […]
